X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    RoboCap: A Robotic Capsule to Improve Gut Drug Delivery

    Once More, M&As In Biotechechnology Industry Are Thriving

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    RoboCap: A Robotic Capsule to Improve Gut Drug Delivery

    Once More, M&As In Biotechechnology Industry Are Thriving

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development FDA Approvals

AstraZeneca’s Enhertu wins keenly-anticipated U.S. breast cancer nod

Content Team by Content Team
5th August 2022
in FDA Approvals, Press Statements
AstraZeneca's Enhertu wins keenly-anticipated U.S. breast cancer nod

AstraZeneca (AZN.L) and Daiichi Sankyo (4568.T) on Friday secured U.S. approval that broadens the use of their therapy Enhertu, for patients with breast cancer, and paves the way for billions in sales.

This is the first-ever U.S. Food and Drug Administration (FDA) approval for a medicine specifically targeting patients with so-called HER2-low breast cancer, the agency said.

Breast cancer can express, at varying levels, a protein called HER2 that contributes to its growth and spread. HER2-low tumours are defined as those whose cells contain lower levels of the HER2 protein on their surface.

The U.S. approval is based on data from a late-stage trial involving over 550 patients with HER2-low breast cancer – most with tumours that were hormone-sensitive – whose disease had spread and who had undergone at least one round of chemotherapy.

The data, unveiled at a scientific conference in June that prompted a standing ovation from the audience, showed Enhertu prolonged survival by an additional 6.4 months in patients with hormone-sensitive tumours.

In the small group of patients with hormone-insensitive tumours, patients on Enhertu lived 6.3 months longer.

The therapy also nearly doubled the time before patients with hormone-sensitive disease began to worsen – a measure known as progression free survival (PFS).

However, Enhertu carries some significant safety concerns.

Enhertu should carry a boxed warning – the FDA’s most serious – to highlight the the risk of a type of lung scarring and fetal toxicity, the regulator said on Friday, adding that the therapy is not recommended for pregnant women.

The drug belongs to class of therapies called antibody drug conjugates (ADC). Enhertu comprises a monoclonal antibody – in this case trastuzumab (also known as Herceptin) – chemically linked to a cell-killing chemotherapy drug.

Enhertu originally won U.S. approval in late 2019 as a third-line treatment for the 15% of breast cancer patients with HER2-positive disease.

This fresh approval – which has come months ahead of the FDA’s expected decision date – opens up a large new patient population and the prospect of billions in additional revenue for its makers.

Enhertu generated sales of $214 million in 2021. AstraZeneca secured partial rights to the Daiichi Sankyo compound three years ago in a deal worth up to $6.9 billion.

About 287,850 new cases of female breast cancer will be diagnosed this year in the United States, the FDA estimates.

Roughly 80% to 85% of those new cases will include patients who express little or no HER2. Of those, 60% are considered as HER2-low.

Previous Post

With $6.26bn In Q1, The Indian Pharma Exports Grew By 8%

Next Post

Why Children Are Better Protected Against COVID-19 & More

Related Posts

FDA Approvals

Food And Drug Administration User Fee Has Been Reauthorized

3rd November 2022
Chinas Institute of Materia Medica Partners With Cyclica on Innovative Drug Repurposing for COVID-19
FDA Approvals

EMA Wants To Limit Immune-Regulating Medications Like FDA

31st October 2022
FDA Approvals

FDA Under Strain To Amend The Accelerated Approval Program

27th October 2022
FDA Approvals

CDC Recommends Novavax COVID Jab To Mix With Pfizer, Moderna

22nd October 2022
FDA Approvals

Rare Illness Study Will Get $38mn FDA Funding Over 4 Years

22nd October 2022
FDA Explores For Ways That Help Tailored Gene Treatment
FDA Approvals

FDA Explores For Ways That Help Tailored Gene Treatment

17th October 2022
Next Post
Why Children Are Better Protected Against COVID-19 & More

Why Children Are Better Protected Against COVID-19 & More

Latest News

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
Facilities & Operation

CPhI Pharma Index Shows Unprecedented Global Pharma Optimism

5th November 2022
$2 Million Gene Therapy Might Become The Standard In The US
Drug Development

$2 Million Gene Therapy Might Become The Standard In The US

5th November 2022
News

Cancer Medicine Prices Jump 53% In Five Years In The U.S

3rd November 2022
FDA Approvals

Food And Drug Administration User Fee Has Been Reauthorized

3rd November 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In